These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22678691)

  • 21. [Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
    Nosaka K; Kawaguchi T
    Nihon Rinsho; 2012 May; 70(5):835-9. PubMed ID: 22620009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
    Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
    J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flow cytometric MRD detection in selected mature B-cell malignancies.
    Böttcher S; Ritgen M; Kneba M
    Methods Mol Biol; 2013; 971():149-74. PubMed ID: 23296963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of SOX11 in mantle cell lymphoma.
    Lu TX; Li JY; Xu W
    Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The minimal residual disease (MRD) in hematological malignancies].
    Yokota S; Okamoto T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of minimal residual disease in acute myeloid leukemia.
    Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
    Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
    Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
    Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
    Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
    Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
    Cazzaniga G; Biondi A
    Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation.
    Darby A; Gribben JG
    Methods Mol Med; 2005; 115():315-31. PubMed ID: 15998976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal residual disease in myeloma: are we there yet?
    Hart AJ; Jagasia MH; Kim AS; Mosse CA; Savani BN; Kassim A
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1790-9. PubMed ID: 22626785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
    Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
    Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
    Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
    Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.